
GHRH + GHRP Combinations: Sermorelin, Ipamorelin & Peptide Stacks
Guide to combining GHRH and GHRP peptides for synergistic growth hormone release. Covers sermorelin + ipamorelin, CJC-1295 + GHRP-6, and other research combinations.
GHRH + GHRP Combinations: The Synergy Explained
The Key Concept
GHRH and GHRP peptides work through different mechanisms. When combined, they produce synergistic growth hormone release—meaning the total effect is greater than either peptide alone.
GHRH alone: ████████ (moderate GH)
GHRP alone: ████████ (moderate GH)
GHRH + GHRP: ████████████████████ (synergistic GH)
This guide explains why this happens and how researchers approach these combinations.
Table of Contents
- Understanding the Two Pathways
- Why Combinations Work
- Common GHRH Peptides
- Common GHRP Peptides
- Popular Combinations
- Research Protocols
- Comparison Table
- Frequently Asked Questions
Understanding the Two Pathways
GHRH Pathway
GHRH (Growth Hormone Releasing Hormone) peptides:
- Bind to GHRH receptors on pituitary
- Stimulate GH synthesis AND release
- Work like a "gas pedal" for GH production
| GHRH Peptide | Notes |
|---|---|
| Sermorelin | GHRH (1-29), original |
| CJC-1295 no DAC | Modified, longer half-life |
| CJC-1295 DAC | Very long half-life (days) |
| Tesamorelin | FDA-approved (lipodystrophy) |
GHRP Pathway
GHRP (Growth Hormone Releasing Peptide) peptides:
- Bind to ghrelin/GHS receptors
- Amplify GH release (less effect on synthesis)
- Work like a "signal amplifier"
| GHRP Peptide | Hunger Effect | Cortisol | Notes |
|---|---|---|---|
| Ipamorelin | Minimal | Minimal | Cleanest profile |
| GHRP-2 | Moderate | Low | Good potency |
| GHRP-6 | High | Moderate | Strongest hunger |
| Hexarelin | Low | Higher | Most potent GH |
Why Combinations Work
Different Receptors, Same Goal
Pituitary Somatotroph Cell
│
┌────────────────┴────────────────┐
│ │
GHRH Receptor Ghrelin Receptor
│ │
↓ ↓
cAMP pathway IP3/Ca2+ pathway
│ │
└────────────┬───────────────────┘
│
↓
Amplified GH Release
The Math
Research consistently shows:
- GHRH alone: X amount of GH release
- GHRP alone: Y amount of GH release
- GHRH + GHRP: Greater than X + Y
This is true synergy—the pathways enhance each other.
Why Not Just Use More of One?
| Approach | Problem |
|---|---|
| High-dose GHRH only | Receptor saturation, diminishing returns |
| High-dose GHRP only | Side effects increase (hunger, cortisol) |
| Moderate both | Synergy achieved without maxing either pathway |
Common GHRH Peptides
Sermorelin
| Property | Value |
|---|---|
| Sequence | GHRH (1-29) |
| Half-life | 10-20 minutes |
| Pros | Most studied, clinical history |
| Cons | Short half-life requires frequent dosing |
CJC-1295 (no DAC)
| Property | Value |
|---|---|
| Sequence | Modified GHRH (1-29) |
| Half-life | ~30 minutes |
| Pros | More stable than sermorelin |
| Cons | Less clinical data |
Also called "Mod GRF 1-29" in research literature.
CJC-1295 with DAC
| Property | Value |
|---|---|
| Sequence | Modified GHRH + Drug Affinity Complex |
| Half-life | Days (binds albumin) |
| Pros | Once or twice weekly dosing |
| Cons | Constant GH elevation, less pulsatile |
Tesamorelin
| Property | Value |
|---|---|
| Status | FDA-approved (Egrifta) |
| Indication | HIV-associated lipodystrophy |
| Pros | Most regulatory data |
| Cons | Single approved indication |
Common GHRP Peptides
Ipamorelin
The "cleanest" GHRP
| Property | Value |
|---|---|
| Hunger increase | Minimal |
| Cortisol increase | Minimal |
| Prolactin effect | Minimal |
| GH release | Moderate-good |
Best for: Those wanting GH release without appetite/cortisol effects
GHRP-2
Balanced profile
| Property | Value |
|---|---|
| Hunger increase | Moderate |
| Cortisol increase | Low |
| Prolactin effect | Minimal |
| GH release | Good |
Best for: Balance of potency and side effect profile
GHRP-6
Strongest hunger effect
| Property | Value |
|---|---|
| Hunger increase | High |
| Cortisol increase | Moderate |
| Prolactin effect | Low |
| GH release | Good |
Best for: Those wanting appetite stimulation (weight gain research)
Hexarelin
Most potent GH release
| Property | Value |
|---|---|
| Hunger increase | Low |
| Cortisol increase | Higher |
| Prolactin effect | Higher |
| GH release | Highest |
Best for: Maximum GH release (but more side effects)
Popular Combinations
Sermorelin + Ipamorelin
The "gentle" stack
Sermorelin (GHRH) + Ipamorelin (GHRP)
↓
Synergistic GH release with minimal side effects
| Pros | Cons |
|---|---|
| Clean side effect profile | Sermorelin short half-life |
| Well-tolerated | May need multiple daily doses |
| Good for long-term protocols |
CJC-1295 no DAC + Ipamorelin
Most popular research combination
CJC-1295 no DAC (GHRH) + Ipamorelin (GHRP)
↓
Extended GHRH action + clean GHRP
| Pros | Cons |
|---|---|
| CJC-1295 lasts longer than sermorelin | Less clinical data than sermorelin |
| Ipamorelin minimal sides | |
| Maintains pulsatile release |
CJC-1295 DAC + Ipamorelin
Extended release version
| Pros | Cons |
|---|---|
| Less frequent GHRH dosing | Constant GH elevation (less natural) |
| Convenience | May cause more side effects long-term |
GHRP-2 + CJC-1295 no DAC
More potent version
| Pros | Cons |
|---|---|
| Stronger GH release than ipamorelin | Moderate hunger increase |
| Good potency |
GHRP-6 + Sermorelin
Appetite stimulation focus
| Pros | Cons |
|---|---|
| Strong appetite increase | Significant hunger |
| Good for weight gain research | Cortisol elevation |
Research Protocols
Timing Principles
| Principle | Rationale |
|---|---|
| Fasted state | Food (especially fats) blunts GH release |
| Bedtime dosing | Aligns with natural GH peak during sleep |
| Morning dosing | Second peak, fasted from overnight |
| Pre-workout | Theoretical performance/recovery benefit |
Common Research Schedules
Twice daily (common):
Morning (fasted): GHRH + GHRP
Bedtime: GHRH + GHRP
Three times daily (aggressive):
Morning (fasted): GHRH + GHRP
Afternoon (fasted): GHRH + GHRP
Bedtime: GHRH + GHRP
Once daily (conservative):
Bedtime: GHRH + GHRP
Saturation Concept
Research suggests there may be a saturation dose for GHRPs—beyond which more peptide doesn't produce more GH. This is why moderate combination dosing often outperforms high single-peptide dosing.
Comparison Table
GHRH Peptides
| Peptide | Half-Life | Clinical Data | Cost | Best For |
|---|---|---|---|---|
| Sermorelin | 10-20 min | Extensive | $$ | Most studied option |
| CJC-1295 no DAC | ~30 min | Moderate | $$ | Longer action |
| CJC-1295 DAC | Days | Limited | $$$ | Convenience |
| Tesamorelin | ~30 min | Extensive | $$$$ | FDA-approved |
GHRP Peptides
| Peptide | GH Release | Hunger | Cortisol | Best For |
|---|---|---|---|---|
| Ipamorelin | Moderate | Low | Low | Clean profile |
| GHRP-2 | Good | Moderate | Low | Balance |
| GHRP-6 | Good | High | Moderate | Appetite stimulation |
| Hexarelin | Highest | Low | Higher | Max GH release |
Combinations
| Combo | Synergy | Side Effects | Notes |
|---|---|---|---|
| Sermorelin + Ipamorelin | Good | Minimal | Conservative |
| CJC-1295 no DAC + Ipamorelin | Good | Minimal | Most popular |
| CJC-1295 no DAC + GHRP-2 | Better | Low-moderate | More potent |
| GHRP-6 + any GHRH | Good | Moderate | Appetite focus |
Frequently Asked Questions
Why not just use HGH directly?
Direct HGH:
- Bypasses pituitary (doesn't stimulate natural production)
- Flat levels (not pulsatile like natural release)
- Potentially suppresses natural GH over time
- More regulatory/legal complexity
GHRH/GHRP combinations:
- Stimulate your own GH release
- Maintain pulsatile pattern
- Support pituitary function
- Generally considered more "physiological"
Can you use GHRP alone without GHRH?
Yes, GHRPs work alone. But:
- You miss the synergistic amplification
- GHRP "amplifies" a signal—GHRH provides more signal to amplify
- Combinations generally more effective per dose
How long until effects are noticed?
- Blood markers (GH, IGF-1): Days to weeks
- Body composition: Weeks to months
- Subjective effects: Variable, weeks typically
Do these peptides shut down natural GH?
Unlike direct HGH, GHRH/GHRP peptides work through natural pathways and generally don't suppress pituitary function. Some research suggests they may even support pituitary health long-term.
Which combination is "best"?
Depends on goals:
- Minimal sides: Sermorelin or CJC-1295 no DAC + Ipamorelin
- Appetite increase: GHRP-6 + any GHRH
- Maximum GH: Hexarelin + CJC-1295 (but more sides)
- Convenience: CJC-1295 DAC + Ipamorelin
Is cycling necessary?
Research approaches vary. Some use continuous protocols, others cycle (e.g., 5 days on, 2 off). Limited data on optimal long-term approaches.
Summary
| Key Point | Details |
|---|---|
| Synergy is real | GHRH + GHRP produces more GH than either alone |
| Different mechanisms | GHRH stimulates, GHRP amplifies |
| Popular combo | CJC-1295 no DAC + Ipamorelin |
| Cleanest option | Sermorelin or CJC-1295 no DAC + Ipamorelin |
| Timing matters | Fasted state, bedtime common |
These combinations represent active research areas with documented synergistic effects on GH release. Individual response varies, and all use should be under appropriate supervision.
References
-
Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-1329.
-
Bowers CY, et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545.
-
Veldhuis JD, et al. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab. 1991;72(1):51-59.
-
Ghigo E, et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in patients with GH deficiency. J Clin Endocrinol Metab. 1994;78(3):693-698.
-
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
-
Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone. J Clin Endocrinol Metab. 2006;91(3):799-805.
-
Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.
Reviewed by: Dr. Research Reviewer, PhD